Zymaxid

Fluoroquinolone Antibiotics
Ophthalmological Anti-infectives

Apply topically to the eye. For topical ophthalmic use only.
Instruct patient on proper instillation of eye solution.
Avoid contamination of the eye solution; do not to touch the tip of the eye dropper to the eye, fingertips, or other surface.

keratitis / Delayed / 5.0-10.0
ocular hemorrhage / Delayed / 1.0-4.0
visual impairment / Early / 1.0-4.0
Stevens-Johnson syndrome / Delayed / 0-1.0
anaphylactoid reactions / Rapid / Incidence not known
laryngeal edema / Rapid / Incidence not known
angioedema / Rapid / Incidence not known

conjunctivitis / Delayed / 5.0-10.0
dyspnea / Early / Incidence not known
blurred vision / Early / Incidence not known
blepharitis / Early / Incidence not known
corneal edema / Early / Incidence not known

lacrimation / Early / 5.0-10.0
ocular irritation / Rapid / 5.0-10.0
ocular discharge / Delayed / 1.0-4.0
ocular pain / Early / 1.0-4.0
xerophthalmia / Early / 1.0-4.0
dysgeusia / Early / 1.0
pruritus / Rapid / Incidence not known
rash / Early / Incidence not known
urticaria / Rapid / Incidence not known
ocular pruritus / Rapid / Incidence not known
headache / Early / Incidence not known
nausea / Early / Incidence not known

Zymaxid

Rx

Ophthalmic fluoroquinolone antibiotic
Indicated for bacterial conjunctivitis
Minimal systemic absorption

1 drop in the affected eye(s) every 2 hours while awake, up to 8 times daily, for 1 day, then 1 drop in the affected eye(s) 2 to 4 times daily while awake for 6 days.

1 drop in the affected eye(s) every 2 hours while awake, up to 8 times daily, for 1 day, then 1 drop in the affected eye(s) 2 to 4 times daily while awake for 6 days.

1 drop to the affected eye(s) every 5 to 15 minutes for 5 doses within 1 hour before the start of the procedure. Perioperative antisepsis with povidone-iodine is recommended. Subconjunctival or intracameral antibiotics at the end of the procedure is optional. The necessity of continuing topical antimicrobials postoperatively has not been established.

†Indicates off-label use

No dosage adjustments are needed.

No dosage adjustments are needed.

There are no drug interactions associated with Gatifloxacin products.

Gatifloxacin/Zymaxid Ophthalmic Sol: 0.5%

8 drops/day in affected eye(s).

8 drops/day in affected eye(s).

8 drops/day in affected eye(s).

8 drops/day in affected eye(s).

8 drops/day in affected eye(s) of 0.3% solution only.

8 drops/day in affected eye(s) of 0.3% solution only.

Gatifloxacin is bactericidal via inhibition of DNA gyrase (topoisomerase II), an enzyme responsible for counteracting the excessive supercoiling of DNA during replication or transcription and topoisomerase IV, an enzyme that helps separate the daughter DNA molecules. In gram-negative bacteria, the primary target is the DNA gyrase A subunit, while the primary target in gram-positive bacteria is generally topoisomerase IV.

Gatifloxacin is administered topically to the eye. Systemic absorption is minimal.

Ophthalmic Route
Following ophthalmic administration, serum concentrations of gatifloxacin are below detectable limits.

Because of the minimal systemic absorption of gatifloxacin after topical ophthalmic administration, there is expected to be minimal risk of maternal and fetal toxicity when administered during pregnancy.

Ophthalmic use of gatifloxacin would result in minimal absorption during breast-feeding. To minimize the amount of drug that reaches the systemic circulation and breast milk, apply pressure over the tear duct by the corner of the eye for 1 minute after ophthalmic administration.